In honor of Melanoma and Skin Cancer Awareness Month, DermTech, Inc. (DMTK) - Get Report ("DermTech"), a leader in precision dermatology enabled by the non-invasive DermTech Smart Sticker ™ platform and its melanoma test, the Pigmented Lesion Assay or PLA, is launching the #Stickit2Melanoma campaign, urging the public to get proactive about skin exams. One in five Americans develop skin cancer by the age of 70, and every hour of every day one American dies from melanoma. It is not only one of the most common cancers diagnosed in the U.S., but also the deadliest of skin cancers. Yet, when diagnosed at a localized stage, the 5-year relative survival rate for melanoma is 99%. Early detection saves lives, and just one annual screening can uncover issues beneath the skin's surface at the most treatable stage.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210503005684/en/
To kick off the campaign, DermTech is pledging up to $1 million over the next four years to raise awareness about the importance of skin exams and making them accessible to everyone. For every #Stickit2Melanoma pledge to schedule a skin exam with a clinician, DermTech will make a $5 donation to its nonprofit partner organizations focused on skin health. DermTech believes it can help stop deaths from melanoma and is steadfast in fulfilling this goal.
"DermTech is fervently committed to reducing melanoma deaths through early detection, and this pledge is just the start to a bigger movement we are hoping to inspire," said John Dobak, M.D., Chief Executive Officer of DermTech. "The technology and science to reduce melanoma deaths through early and accurate detection is here, so no one should ever have to die from this cancer. To make this possible, we're calling on everyone-dermatologists and patients alike-to galvanize their communities to join our pledge today."
#Stickit2Melanoma aims to bring awareness to the dangers of late-stage melanoma and the life-saving effects of scheduling skin exams. DermTech's donations will help support events, educational content and programs to amplify a variety of voices who are joining our fight to end melanoma deaths. DermTech is proud to serve as a partner to the dermatology community and an ally to skin cancer organizations across the country.
To join #Stickit2Melanoma, schedule a skin exam with your doctor, take the pledge at www.DermTech.com/Pledge and encourage your community to do the same. Let's unite together to end melanoma deaths.
DermTech is the leading genomics company in dermatology and is creating a new category of medicine, precision dermatology, enabled by our non-invasive skin genomics platform. DermTech's mission is to transform dermatology with our non-invasive skin genomics platform, to democratize access to high quality dermatology care, and to improve the lives of millions. DermTech provides genomic analysis of skin samples collected non-invasively using an adhesive patch rather than a scalpel. DermTech markets and develops products that facilitate the early detection of skin cancers, and is developing products that assess inflammatory diseases and customize drug treatments. For additional information on DermTech, please visit DermTech's investor relations site at: www.dermtech.com.
This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. The expectations, estimates, and projections of DermTech may differ from its actual results and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, expectations with respect to: the performance, patient benefits, cost-effectiveness, commercialization and adoption of DermTech's products and the market opportunity therefor. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the control of DermTech and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the outcome of any legal proceedings that may be instituted against DermTech; (2) DermTech's ability to obtain additional funding to develop and market its products; (3) the existence of favorable or unfavorable clinical guidelines for DermTech's tests; (4) the reimbursement of DermTech's tests by Medicare and private payors; (5) the ability of patients or healthcare providers to obtain coverage of or sufficient reimbursement for DermTech's products; (6) DermTech's ability to grow, manage growth and retain its key employees; (7) changes in applicable laws or regulations; (8) the market adoption and demand for DermTech's products and services together with the possibility that DermTech may be adversely affected by other economic, business, and/or competitive factors; and (9) other risks and uncertainties included in (x) the "Risk Factors" section of the most recent Annual Report on Form 10-K filed by DermTech with the Securities and Exchange Commission (the "SEC"), and (y) other documents filed or to be filed by DermTech with the SEC. DermTech cautions that the foregoing list of factors is not exclusive. You should not place undue reliance upon any forward-looking statements, which speak only as of the date made. DermTech does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210503005684/en/